132 related articles for article (PubMed ID: 32826655)
1. Infliximab-Induced Granulomatous Vasculitis With Amyloid Deposition in the Tongue of a Patient With Behçet Disease.
Iwasaki S; Watanabe T; Tsuji T; Otsuka T; Makita K; Fukasawa Y; Ishizu A
J Clin Rheumatol; 2021 Dec; 27(8S):S710-S712. PubMed ID: 32826655
[No Abstract] [Full Text] [Related]
2. Use of infliximab and other biologics in Behçet disease.
Li J; Fernando S; Herkes G
Intern Med J; 2014 Jan; 44(1):96-100. PubMed ID: 24450526
[TBL] [Abstract][Full Text] [Related]
3. Early treatment with infliximab in bilateral occlusive vasculitis as a presenting manifestation of Behçet' disease.
Bañeros-Rojas P; Berrozpe-Villabona C; Peraza-Nieves JE; Díaz-Valle D
Arch Soc Esp Oftalmol; 2015 Jun; 90(6):285-8. PubMed ID: 25443189
[TBL] [Abstract][Full Text] [Related]
4. Infliximab effects compared to conventional therapy in the management of retinal vasculitis in Behçet disease.
Tabbara KF; Al-Hemidan AI
Am J Ophthalmol; 2008 Dec; 146(6):845-50.e1. PubMed ID: 18929351
[TBL] [Abstract][Full Text] [Related]
5. Behçet disease-associated rhabdomyolysis treated with infliximab.
Hambly TW; Wong NL; Yun J
Intern Med J; 2020 May; 50(5):642-643. PubMed ID: 32431040
[No Abstract] [Full Text] [Related]
6. Neurological complications of Behçet's syndrome.
Kidd D
Curr Neurol Neurosci Rep; 2012 Dec; 12(6):675-9. PubMed ID: 23007835
[TBL] [Abstract][Full Text] [Related]
7. Infliximab for Behçet disease with aortic involvement: two novel case reports without concurrent use of immunosuppressive agents or corticosteroids.
Rokutanda R; Okada M; Yamaguchi K; Nozaki T; Deshpande GA; Kishimoto M
Mod Rheumatol; 2013 Mar; 23(2):412-3. PubMed ID: 22821442
[No Abstract] [Full Text] [Related]
8. [10th International Conference on Behçet Syndrome. Berlin, June 27-29, 2002].
Weschler B
Rev Med Interne; 2002 Oct; 23(10):808-9. PubMed ID: 12428481
[No Abstract] [Full Text] [Related]
9. Sustained remission after infliximab in a child with vasculitis refractory to conventional immunosuppressives including interferon-alpha.
Evereklioglu C; Borlu M
Br J Ophthalmol; 2008 Aug; 92(8):1034, 1148-9. PubMed ID: 18653594
[No Abstract] [Full Text] [Related]
10. Refractory neuro-Behçet treated by tocilizumab: a case report.
Urbaniak P; Hasler P; Kretzschmar S
Clin Exp Rheumatol; 2012; 30(3 Suppl 72):S73-5. PubMed ID: 23020826
[TBL] [Abstract][Full Text] [Related]
11. Mimicry between intestinal Behçet's disease and inflammatory bowel disease.
Rodrigues-Pinto E; Magro F; Pimenta S; Guimarães J; Macedo G
J Crohns Colitis; 2014 Jul; 8(7):714-5. PubMed ID: 24389388
[No Abstract] [Full Text] [Related]
12. Life-threatening vasculo-Behçet following discontinuation of infliximab after three years of complete remission.
Magro-Checa C; Salvatierra J; Rosales-Alexander JL; Orgaz-Molina J; Raya-Álvarez E
Clin Exp Rheumatol; 2013; 31(3 Suppl 77):96-8. PubMed ID: 23739315
[TBL] [Abstract][Full Text] [Related]
13. Infliximab for the treatment of posterior uveitis with retinal neovascularization in Behçet disease.
Giansanti F; Barbera ML; Virgili G; Pieri B; Emmi L; Menchini U
Eur J Ophthalmol; 2004; 14(5):445-8. PubMed ID: 15506610
[TBL] [Abstract][Full Text] [Related]
14. Timing of recurrent uveitis in patients with Behcet's disease receiving infliximab treatment.
Yamada Y; Sugita S; Tanaka H; Kamoi K; Takase H; Mochizuki M
Br J Ophthalmol; 2011 Feb; 95(2):205-8. PubMed ID: 20542984
[TBL] [Abstract][Full Text] [Related]
15. Good response to infliximab in a patient with deep vein thrombosis associated with Behçet disease.
Yoshida S; Takeuchi T; Yoshikawa A; Ozaki T; Fujiki Y; Hata K; Makino S; Hanafusa T
Mod Rheumatol; 2012 Sep; 22(5):791-5. PubMed ID: 22245952
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of efficacy of infliximab for retinal vasculitis and extraocular symptoms in Behçet disease.
Umazume A; Kezuka T; Usui Y; Suzuki J; Goto H
Jpn J Ophthalmol; 2018 May; 62(3):390-397. PubMed ID: 29582190
[TBL] [Abstract][Full Text] [Related]
17. An incomplete form of childhood Behçet's disease treated with infliximab.
Caporuscio S; Pranteda G; Nistico S; Maucione T; Canzoni M; Stefani A; Muscianese M; Fanto M; Sorgi M
Int J Immunopathol Pharmacol; 2014; 27(3):445-8. PubMed ID: 25280037
[TBL] [Abstract][Full Text] [Related]
18. Infliximab treatment of severe genital ulcers associated with Behçet disease.
Kasugai C; Watanabe D; Mizutani K; Masuda Y; Zako M; Mukai T; Tamada Y; Matsumoto Y
J Am Acad Dermatol; 2010 Jan; 62(1):162-164. PubMed ID: 20082903
[No Abstract] [Full Text] [Related]
19. Effects of anti-TNF-alpha antibody infliximab in refractory entero-Behcet's disease.
Iwata S; Saito K; Yamaoka K; Tsujimura S; Nawata M; Suzuki K; Tanaka Y
Rheumatology (Oxford); 2009 Aug; 48(8):1012-3. PubMed ID: 19465589
[No Abstract] [Full Text] [Related]
20. [Effectiveness of infliximab in patients with Behçet syndrome and severe uveoretinitis. Report of five cases].
Merino G; Varas G; Díaz G; Gutiérrez M; Massardo L; Pacheco D; Villarroel F; Cuchacovich M
Rev Med Chil; 2006 Jul; 134(7):875-82. PubMed ID: 17130971
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
